<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318305</url>
  </required_header>
  <id_info>
    <org_study_id>392-05</org_study_id>
    <nct_id>NCT00318305</nct_id>
  </id_info>
  <brief_title>Patient Preference With Visicol Tablet Preparation for Colonoscopy</brief_title>
  <official_title>Patient Preference and Acceptance With Sodium Phosphate Tablet Preparation for Colonoscopy: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InKine Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine patient preference and acceptance of tablet sodium&#xD;
      phosphate bowel preparation in patients who had polyethylene glycol (PEG) solution for their&#xD;
      prior colonoscopy. This study will provide answers related to the patient preferences and&#xD;
      their acceptance of this new method of bowel preparation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">53</enrollment>
  <condition>Preparation for Colonoscopy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Scheduled colonoscopy list will be reviewed to identify potential subjects for recruitment.&#xD;
        A cover letter will be sent to the potential study subject with tablet preparation as an&#xD;
        alternative to Golytely preparation ( PEG). For subjects who are willing to participate, a&#xD;
        prescription for 28 tablet sodium phosphate bowel preparation as outlined in appendix: A&#xD;
        will be mailed. A questionnaire will be given to the patients prior to their colonoscopy to&#xD;
        identify their preferences regarding bowel preparation and their acceptance ( see appendix:&#xD;
        B).&#xD;
&#xD;
        A separate validated questionnaire will be given to participating physicians after the&#xD;
        procedure, to quantitate the colonic cleansing (appendix : C). Adverse events will be&#xD;
        documented. A statistical analysis of the results will be done at the end of the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior colonoscopy with PEG solution in the past one year&#xD;
&#xD;
          -  Must be able to swallow tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients below 18 years and above 100 years.&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Chronic renal failure&#xD;
&#xD;
          -  Pre-existing electrolyte disorder&#xD;
&#xD;
          -  Pre-existing mega-colon or a motility disorder.&#xD;
&#xD;
          -  Patients with pre-existing seizure disorder.&#xD;
&#xD;
          -  Patients scheduled for colonoscopy after 1:00 p.m. will be excluded from the study.&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suryakanth R. Gurudu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>April 24, 2006</study_first_submitted>
  <study_first_submitted_qc>April 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2006</study_first_posted>
  <last_update_submitted>December 1, 2009</last_update_submitted>
  <last_update_submitted_qc>December 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Suryakanth Gurudu, MD</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

